HLA Binding Assays

HLA Binding Assays

Class II: Class II HLA binding assays may be used to measure affinity of putative epitopes for multiple HLA alleles. EpiVax employs a competition-based HLA binding assay originally described by Steere et al. [1] and adapted for commercial use by EpiVax. Our assay employs highly-purified Class II molecules. This assay format is far superior in sensitivity and specificity compared to cell-based assay formats. Based on a 7 concentration peptide titration, a non-linear regression analysis is performed and an IC50 value is calculated.

Binding assays are performed on up to seven alleles that include: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0901, DRB1*1101, and DRB1*1501.


Researchers working in the labs at EpiVax in Providence. From left, Mitchell McAllister, research associate, Olivia Morin, research associate. PBN PHOTO/MICHAEL SALERNO

[1] Assay described in: Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006 Apr 17;203(4):961-71.

We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. For a recent interview highlighting our CEO’s latest ideas, click on the video: